Please enter a valid month/year e.g. 01/2015

Pick a date between April 2016 and April 2017

Showing 1 to 9 of 9
Title Reference number Published Last updated
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) Reference number:TA438 TA00438 Published:March 2017 20170301 Last updated:March 2017 20170329
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) Reference number:TA436 TA00436 Published:March 2017 20170301 Last updated:March 2017 20170322
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Reference number:TA422 TA00422 Published:December 2016 20161201 Last updated:December 2016 20161221
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer Reference number:TA416 TA00416 Published:October 2016 20161001 Last updated:October 2016 20161026
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Reference number:TA406 TA00406 Published:September 2016 20160901 Last updated:September 2016 20160928
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer Reference number:TA411 TA00411 Published:September 2016 20160901 Last updated:September 2016 20160928
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin Reference number:TA402 TA00402 Published:August 2016 20160801 Last updated:August 2016 20160824
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer Reference number:TA403 TA00403 Published:August 2016 20160801 Last updated:August 2016 20160824
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer Reference number:TA395 TA00395 Published:June 2016 20160601 Last updated:June 2016 20160622